Shockless Implant Evaluation
- Conditions
- Ventricular TachycardiaVentricular Fibrillation
- Interventions
- Device: Implantable defibrillator
- Registration Number
- NCT00800384
- Lead Sponsor
- Boston Scientific Corporation
- Brief Summary
This trial will assess the safety of defibrillator testing and the influence of defibrillation testing on the efficacy of clinical shocks.
The trial will test the hypothesis that implantable cardioverter defibrillator (ICD) implantation without defibrillation testing (DT) is non-inferior to implantation with testing against the composite endpoint of ineffective first appropriate clinical shock or arrhythmic death.
It will also test the hypothesis, that defibrillation testing increases the peri-operative (30 days) complication rate of ICD implantation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 2500
- Age ≥ 18 years
- Patients undergoing initial implant of an ICD or CRT-D device (can be upgrade from a pacemaker)
- Patients, who in the opinion of their treating physicians are ineligible for either strategy (DT or no DT)
- Patients on active transplant list
- Patients unwilling to provide informed consent
- Patients not available for follow-up
- Pregnancy or women of child bearing potential not following an effective method of contraception
- Anticipated right sided implantation of the ICD generator
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Implantable defibrillator ICD implant with defibrillation testing 1 Implantable defibrillator ICD implant without defibrillation testing
- Primary Outcome Measures
Name Time Method First Occurrence of the Composite of Failed First Appropriate Clinical Shock From the Implantable Cardioverter Defibrillator (ICD) or Arrhythmic Death Mean follow-up of 3.1 years The number of patients having experienced either an appropriate inefficient shock and/or arrhythmic death during the follow-up time frame of 3.1 years is compared between both groups.
- Secondary Outcome Measures
Name Time Method Perioperative Complication Rate 30 days A predefined set of expected complications attributed to defibrillation testing during implant procedure was analyzed in both groups.
Trial Locations
- Locations (85)
The Royal Melbourne Hospital
🇦🇺Melbourne, Australia
Landesklinikum St. Poelten
🇦🇹St. Poelten, Austria
Allgemeines Krankenhaus Wien
🇦🇹Vienna, Austria
Wilhelminenspital
🇦🇹Vienna, Austria
Klinikum Wels - Grieskirchen
🇦🇹Wels, Austria
University of Alberta Hospital
🇨🇦Edmonton, Alberta, Canada
Royal Jubilee Hospital
🇨🇦Victoria, British Columbia, Canada
St. Boniface General Hospital
🇨🇦Winnipeg, Manitoba, Canada
Queen Elizabeth II Health Sciences Center
🇨🇦Halifax, Nova Scotia, Canada
Hamilton General Hospital
🇨🇦Hamilton, Ontario, Canada
Scroll for more (75 remaining)The Royal Melbourne Hospital🇦🇺Melbourne, Australia